Gyre Therapeutics (NASDAQ:GYRE) Downgraded to Hold Rating by Wall Street Zen
by Teresa Graham · The Cerbat GemWall Street Zen lowered shares of Gyre Therapeutics (NASDAQ:GYRE – Free Report) from a buy rating to a hold rating in a research report released on Saturday.
GYRE has been the topic of several other reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.00.
View Our Latest Report on GYRE
Gyre Therapeutics Trading Down 3.2%
Gyre Therapeutics stock opened at $7.55 on Friday. The stock has a 50-day moving average price of $7.96 and a two-hundred day moving average price of $7.78. Gyre Therapeutics has a 12 month low of $6.11 and a 12 month high of $12.62. The company has a market capitalization of $727.29 million, a PE ratio of 755.76 and a beta of 1.97.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a return on equity of 11.25% and a net margin of 4.31%.The firm had revenue of $37.20 million for the quarter, compared to the consensus estimate of $36.30 million.
Hedge Funds Weigh In On Gyre Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its holdings in Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Gyre Therapeutics by 132.4% in the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after purchasing an additional 7,361 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Gyre Therapeutics by 72.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock valued at $220,000 after purchasing an additional 13,074 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Gyre Therapeutics in the 3rd quarter valued at $267,000. Finally, Alliancebernstein L.P. increased its position in shares of Gyre Therapeutics by 9.5% during the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after buying an additional 1,900 shares during the period. 23.99% of the stock is owned by institutional investors and hedge funds.
About Gyre Therapeutics
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.